$165 Million is the total value of Birchview Capital, LP's 165457 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 19.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMY | Buy | BRISTOL-MYERS SQUIBB CO | $46,592,000 | +6.4% | 792,386 | +0.8% | 28.16% | -27.5% |
| AXDX | ACCELERATE DIAGNOSTICS INC | $33,258,000 | +82.0% | 2,193,795 | 0.0% | 20.10% | +24.0% | |
| AWH | New | ASPIRA WOMEN'S HEALTH INC | $12,661,000 | – | 3,297,247 | +100.0% | 7.65% | – |
| QDEL | Buy | QUIDEL CORP | $11,398,000 | +138.6% | 50,944 | +4.3% | 6.89% | +62.6% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $9,516,000 | +48.6% | 78,000 | +5.4% | 5.75% | +1.2% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $4,508,000 | +16.0% | 93,000 | +1.1% | 2.72% | -21.0% |
| BLUE | New | BLUEBIRD BIO INC | $3,662,000 | – | 60,000 | +100.0% | 2.21% | – |
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $3,182,000 | +11.9% | 168,000 | +13.5% | 1.92% | -23.8% |
| BIIB | BIOGEN INC | $2,943,000 | -15.4% | 11,000 | 0.0% | 1.78% | -42.4% | |
| BMYRT | BMY CVR RTS 03/31/21right | $2,531,000 | -5.8% | 706,848 | 0.0% | 1.53% | -35.8% | |
| OXFD | OXFORD IMMUNOTEC GLOBAL PLC | $2,214,000 | +40.4% | 170,303 | 0.0% | 1.34% | -4.4% | |
| UTHR | UNITED THERAPEUTICS CORP | $2,178,000 | +27.6% | 18,000 | 0.0% | 1.32% | -13.1% | |
| SLNO | Buy | SOLENO THERAPEUTICS INC | $1,836,000 | +282.5% | 826,899 | +310.4% | 1.11% | +160.6% |
| MASI | MASIMO CORP | $1,824,000 | +28.7% | 8,000 | 0.0% | 1.10% | -12.3% | |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $1,799,000 | +149.9% | 260,000 | +44.4% | 1.09% | +70.1% |
| XLRN | ACCELERON PHARMA INC | $1,779,000 | +6.0% | 18,672 | 0.0% | 1.08% | -27.8% | |
| CCXI | CHEMOCENTRYX INC | $1,726,000 | +43.2% | 30,000 | 0.0% | 1.04% | -2.4% | |
| CFRX | CONTRAFECT CORP | $1,634,000 | +10.9% | 255,700 | 0.0% | 0.99% | -24.4% | |
| ARNA | ARENA PHARMACEUTICALS INC | $1,385,000 | +49.9% | 22,000 | 0.0% | 0.84% | +2.1% | |
| ALBO | ALBIREO PHARMA INC | $1,272,000 | +61.8% | 48,000 | 0.0% | 0.77% | +10.3% | |
| EPZM | Buy | EPIZYME INC | $1,124,000 | +20.7% | 70,000 | +16.7% | 0.68% | -17.8% |
| ETRN | New | EQUITRANS MIDSTREAM CORPORATIO | $1,106,000 | – | 133,050 | +100.0% | 0.67% | – |
| GTHX | G1 THERAPEUTICS INC | $970,000 | +120.0% | 40,000 | 0.0% | 0.59% | +49.9% | |
| MYOK | New | MYOKARDIA INC | $966,000 | – | 10,000 | +100.0% | 0.58% | – |
| HROW | HARROW HEALTH INC | $938,000 | +36.3% | 180,000 | 0.0% | 0.57% | -7.0% | |
| VNDA | VANDA PHARMACEUTICALS INC | $915,000 | +10.4% | 80,000 | 0.0% | 0.55% | -24.8% | |
| IMGN | IMMUNOGEN INC | $874,000 | +34.9% | 190,000 | 0.0% | 0.53% | -8.2% | |
| ODT | ODONATE THERAPEUTICS INC | $847,000 | +53.4% | 20,000 | 0.0% | 0.51% | +4.5% | |
| CORT | CORCEPT THERAPEUTICS INC | $841,000 | +41.6% | 50,000 | 0.0% | 0.51% | -3.6% | |
| GILD | Sell | GILEAD SCIENCES INC | $769,000 | -48.6% | 10,000 | -50.0% | 0.46% | -64.9% |
| BHVN | BIOHAVEN PHARMACEUTICAL HOLDING CO LTD | $731,000 | +115.0% | 10,000 | 0.0% | 0.44% | +46.4% | |
| CLR | New | CONTINENTAL RESOURCES INC | $677,000 | – | 38,600 | +100.0% | 0.41% | – |
| FOLD | AMICUS THERAPEUTICS INC | $573,000 | +63.2% | 38,000 | 0.0% | 0.35% | +11.3% | |
| TBIO | TRANSLATE BIO INC | $538,000 | +79.9% | 30,000 | 0.0% | 0.32% | +22.6% | |
| ARVN | ARVINAS INC | $503,000 | -16.7% | 15,000 | 0.0% | 0.30% | -43.3% | |
| NARI | New | INARI MEDICAL INC | $484,000 | – | 10,000 | +100.0% | 0.29% | – |
| STOK | STOKE THERAPEUTICS INC | $477,000 | +4.1% | 20,000 | 0.0% | 0.29% | -29.1% | |
| ICPT | INTERCEPT PHARMACEUTICALS INC | $398,000 | -23.9% | 8,300 | 0.0% | 0.24% | -48.1% | |
| XNCR | XENCOR INC | $398,000 | +8.2% | 12,300 | 0.0% | 0.24% | -26.1% | |
| PGNY | PROGYNY INC | $387,000 | +21.7% | 15,000 | 0.0% | 0.23% | -17.0% | |
| VYGR | VOYAGER THERAPEUTICS INC | $379,000 | +38.3% | 30,000 | 0.0% | 0.23% | -5.8% | |
| PXD | PIONEER NATURAL RESOURCES CO | $371,000 | +39.0% | 3,800 | 0.0% | 0.22% | -5.5% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $363,000 | +57.8% | 30,000 | 0.0% | 0.22% | +7.4% | |
| OVV | New | OVINTIV INC | $328,000 | – | 34,350 | +100.0% | 0.20% | – |
| IFRX | Sell | INFLARX NV | $321,000 | -23.6% | 70,000 | -36.4% | 0.19% | -48.0% |
| TGTX | TG THERAPEUTICS INC | $292,000 | +97.3% | 15,000 | 0.0% | 0.18% | +34.4% | |
| WKHS | Sell | WORKHORSE GROUP INC | $261,000 | +480.0% | 15,000 | -40.0% | 0.16% | +295.0% |
| APLS | APELLIS PHARMACEUTICALS INC | $261,000 | +22.0% | 8,000 | 0.0% | 0.16% | -16.8% | |
| DRNA | DICERNA PHARMACEUTICALS INC | $254,000 | +38.0% | 10,000 | 0.0% | 0.15% | -5.5% | |
| YTEN | YIELD10 BIOSCIENCE INC | $118,000 | +66.2% | 18,952 | 0.0% | 0.07% | +12.7% | |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $95,000 | +137.5% | 20,000 | 0.0% | 0.06% | +62.9% | |
| EQM | Exit | EQM MIDSTRM PRTNERS LP LTDunit ltd partn | $0 | – | -51,250 | -100.0% | -0.54% | – |
| VRML | Exit | VERMILLION INC | $0 | – | -3,221,933 | -100.0% | -2.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2020-09-25
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACCELERATE DIAGNOSTICS INC | 36 | Q3 2023 | 34.6% |
| QUIDELORTHO CORP | 36 | Q3 2023 | 8.6% |
| MASIMO CORP | 36 | Q3 2023 | 2.2% |
| PIONEER NATURAL RESOURCES CO (PXD) | 36 | Q3 2023 | 0.7% |
| XENCOR INC | 35 | Q3 2023 | 0.4% |
| NEUROCRINE BIOSCIENCES INC | 33 | Q3 2023 | 7.4% |
| CORCEPT THERAPEUTICS INC | 32 | Q3 2023 | 1.2% |
| BIOGEN INC | 31 | Q2 2022 | 3.1% |
| CONTRAFECT CORP | 30 | Q3 2022 | 1.6% |
| YIELD10 BIOSCIENCE INC | 26 | Q3 2023 | 0.6% |
View Birchview Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SOLENO THERAPEUTICS INC | March 19, 2019 | 742,635 | 2.3% |
| YIELD10 BIOSCIENCE, INC. | December 29, 2017 | 186,079 | 2.2% |
| HANSEN MEDICAL INC | February 16, 2016 | ? | ? |
| METABOLIX, INC. | June 23, 2015 | 749,696 | 2.8% |
View Birchview Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3/A | 2024-02-20 |
| 4/A | 2024-02-20 |
| SC 13G/A | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-04-07 |
| 4 | 2023-03-27 |
| 3 | 2023-02-13 |
View Birchview Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.